NYMX Share Price

Open 3.89 Change Price %
High 3.98 1 Day 0.02 0.52
Low 3.79 1 Week -0.14 -3.48
Close 3.88 1 Month 0.52 15.48
Volume 59518 1 Year 0.48 14.12
52 Week High 5.10
52 Week Low 2.67
NYMX Important Levels
Resistance 2 4.06
Resistance 1 3.98
Pivot 3.88
Support 1 3.78
Support 2 3.70
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
AAPL 156.07 -1.68%
More..
NASDAQ USA Top Gainers Stocks
RITT 0.02 100.00%
ALNY 113.84 51.71%
LOCM 0.09 50.00%
VALV 0.03 50.00%
HAUP 0.08 33.33%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LTRE 2.80 20.69%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
AMCF 0.01 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
ORIG 0.08 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Nymox Pharmaceutical Corporation (NASDAQ: NYMX)

NYMX Technical Analysis 3
As on 20th Sep 2017 NYMX Share Price closed @ 3.88 and we RECOMMEND Buy for LONG-TERM with Stoploss of 3.58 & Buy for SHORT-TERM with Stoploss of 3.77 we also expect STOCK to react on Following IMPORTANT LEVELS.
NYMX Target for September
1st Target up-side 4.03
2nd Target up-side 4.24
3rd Target up-side 4.45
1st Target down-side 3.43
2nd Target down-side 3.22
3rd Target down-side 3.01
NYMX Other Details
Segment EQ
Market Capital 242214432.00
Sector Healthcare
Industry Diagnostic Substances
Offical website http://www.nymox.com
NYMX Address
NYMX
9900 Cavendish Boulevard
Suite 306
Saint Laurent, QC H4M 2V2
Canada
Phone: 800-936-9669
Fax: 514-332-2227
NYMX Latest News
Interactive Technical Analysis Chart Nymox Pharmaceutical Corporation ( NYMX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Nymox Pharmaceutical Corporation
NYMX Business Profile
Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. The Company focuses on developing NX-1207, a treatment for benign prostatic hyperplasia (BPH) which is in Phase III trials in the United States. The Company has research and development (R&D) pipeline of products in development for the treatment of such conditions and diseases as enlarged prostate (benign prostatic hyperplasia (BPH)), Alzheimer�s disease (AD), E. coli O157:H7 contamination of food and drink products, and bacterial infections and for the diagnosis of AD and other indications. The Company is in the preclinical stage of developing therapeutic products for oncological indications based on technology licensed from the Massachusetts General Hospital. Nymox has a number of diagnostic markers and technologies, including a patented platform for point-of-care testing, and has tests utilizing these technologies in the early stages of development.